Journal
GENES
Volume 11, Issue 6, Pages -Publisher
MDPI
DOI: 10.3390/genes11060704
Keywords
TP53; mutation; CRISPR; Cas9 gene editing; base editing; prime editing; epigenome regulation; clinical trial
Categories
Funding
- RSF [19-74-10022]
- Russian Science Foundation [19-74-10022] Funding Source: Russian Science Foundation
Ask authors/readers for more resources
TheTP53gene encodes the transcription factor and oncosuppressor p53 protein that regulates a multitude of intracellular metabolic pathways involved in DNA damage repair, cell cycle arrest, apoptosis, and senescence. In many cases, alterations (e.g., mutations of theTP53gene) negatively affect these pathways resulting in tumor development. Recent advances in genome manipulation technologies, CRISPR/Cas9, in particular, brought us closer to therapeutic gene editing for the treatment of cancer and hereditary diseases. Genome-editing therapies for blood disorders, blindness, and cancer are currently being evaluated in clinical trials. Eventually CRISPR/Cas9 technology is expected to targetTP53as the most mutated gene in all types of cancers. A majority ofTP53mutations are missense which brings immense opportunities for the CRISPR/Cas9 system that has been successfully used for correcting single nucleotides in various models, both in vitro and in vivo. In this review, we highlight the recent clinical applications of CRISPR/Cas9 technology for therapeutic genome editing and discuss its perspectives for editingTP53and regulating transcription of p53 pathway genes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available